{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-22-013559","form_type":"8-K","ticker":"BEAM","cik":"0001745999","company_name":"Beam Therapeutics Inc.","filed_at":"2022-08-01T23:59:59+00:00","discovered_at":"2026-05-14T18:03:56.887631+00:00","generated_at":"2026-06-24T06:34:27.649171+00:00","sec_items":["8.01","9.01"],"event_type":"regulatory","sentiment":"negative","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"FDA places clinical hold on Beam's BEAM-201 IND for T-ALL/T-LL","bullets":["FDA clinical hold on BEAM-201 IND for relapsed/refractory T-cell acute lymphoblastic leukemia/T-cell lymphoblastic lymphoma.","Beam informed via FDA email on July 29, 2022; IND submitted end of June.","BEAM-201 is an anti-CD7, multiplex-edited allogeneic CAR-T candidate.","FDA to provide official clinical hold letter within 30 days; Beam plans updates after discussions."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-22-013559","json":"https://secwatch.observer/filing/0000950170-22-013559.json","markdown":"https://secwatch.observer/filing/0000950170-22-013559.md","text":"https://secwatch.observer/filing/0000950170-22-013559.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1745999/000095017022013559/0000950170-22-013559-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1745999/000095017022013559/beam-20220801.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-24T06:34:27.649171+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}